Article, News
Prescient (ASX:PTX) unveils exciting CellPryme-A data at world’s largest CAR-TCR meeting
Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR Summit in Boston, MA. The summit is one of the…
News
Cancer therapy renaissance
The cancer drug market could be on the cusp of a timely renaissance as new therapies come to the forefront of treatment, with around 25,000…
News
Prescient Therapeutics to unveil CellPryme-A platform at CAR-TCR summit in Boston
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit in Boston on September 19 to 22, during which the…
Article, News
HealthKick Podcast: PTX partners with the US’s largest cancer centre on personalised treatment
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. …
News
Prescient Therapeutics hails collaboration with MD Anderson Cancer Center for blood cancer therapy
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the company’s strategic collaboration agreement with the University of Texas MD…
News
3 major milestones in 8 weeks as biotech links with US giant
ASX-listed biotech Prescient Therapeutics is crossing a major inflection point on the back of three milestone announcements made within a span of less than eight…
News
Prescient Therapeutics tops-up cash reserves to progress innovative cancer therapies
Prescient Therapeutics tops-up cash reserves to progress innovative cancer therapies
Article, News
Prescient joins up with renowned US cancer centre in fight against blood cancer
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. Clinical stage…
Article, News
Prescient Therapeutics (ASX:PTX) teams up with prestigious cancer centre in the US
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The clinical-stage oncology player entered into a strategic agreement with The…
Article, News
Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
“We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for…